HANNOVER, Germany--(BUSINESS WIRE)--Digilab, Inc. today announced it has reached an important milestone in its Peptidomics collaboration with Abbott Molecular. In the first phase of the project, Digilab has identified candidate biomarkers for lung cancer using its proprietary Peptidomics® Differential Peptide Display (DPD) technology platform. Abbott has exercised its right to evaluate option candidate markers for further use. Abbott has the option to acquire an exclusive royalty-bearing license from Digilab to such candidate markers.
